Try our beta test site
84 studies found for:    Open Studies | GVHD AND acute
Show Display Options
Rank Status Study
1 Recruiting Safety Follow-up of Treatment With Remestemcel-L in Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
Condition: Grades B-D Acute Graft Versus Host Disease
2 Recruiting Prophylaxis Roles of IL-2 Treatment on Acute GVHD After Transplantation
Condition: Acute Graft-versus-host Disease
Intervention: Drug: Interleukin-2
3 Recruiting Mesenchymal Stromal Cells for Acute Graft Versus Host Disease
Condition: Acute GVH Disease
Intervention: Biological: Mesenchymal stromal cell therapy
4 Recruiting Biomarkers for Acute Graft-versus-host Disease
Condition: Acute GVH Disease
Intervention: Other: no intervention
5 Recruiting Ectoin Dermatitis Cream 7% as First-line Therapy of Acute Skin Graft Versus Host Disease
Condition: Acute Graft Versus Host Disease in Skin
6 Recruiting MicroRNAs as Diagnostic and Predictive Biomarkers for Acute Graft Versus Host Disease
Condition: Acute GVH Disease
Intervention: Other: Peripheral Venipuncture or Blood draw from Central Line
7 Recruiting Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
Condition: Acute Graft Versus Host Disease
Interventions: Drug: natalizumab;   Drug: steroids
8 Not yet recruiting Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease
Condition: Acute-graft-versus-host Disease
Interventions: Drug: Cannabidiol;   Drug: Methylprednisolone;   Drug: Calcineurin inhibitor
9 Recruiting Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
Condition: Corticosteroid Refractory Acute Graft vs Host Disease
Interventions: Drug: Ruxolitinib;   Drug: Best Available Therapy (BAT)
10 Recruiting UVADEX® and ECP for the Treatment of Pediatric Patients With Steroid Refractory Acute Graft Versus Host Disease
Condition: Steroid Refractory Acute Graft Versus Host Disease
Intervention: Drug: UVADEX® (methoxsalen) Sterile Solution in Conjunction with the THERAKOS® CELLEX® Photopheresis System
11 Recruiting A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)
Condition: Acute GVHD
Interventions: Drug: Sirolimus;   Drug: Prednisone
12 Recruiting Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease
Conditions: Acute Graft-versus-Host Disease;   Allogeneic Stem Cell Transplant
Intervention: Procedure: Blood samples
13 Recruiting Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease
Conditions: Acute Graft-versus-host Disease;   Acute GVHD;   Chronic Graft-versus-host Disease;   Chronic GVHD
Interventions: Procedure: Skin punch biopsy;   Procedure: Peripheral blood draw
14 Recruiting MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHD
Condition: Acute Graft-versus-host Disease
Interventions: Drug: CD25 monoclonal antibody;   Drug: calcineurin inhibitors;   Biological: MSCs
15 Recruiting Study of PRO 140 for Prophylaxis of Acute GVHD in Patients With AML or MDS Undergoing Allogeneic Stem-Cell Transplant.
Conditions: Graft vs Host Disease;   Leukemia, Myeloid, Acute;   Myelodysplastic Syndromes
Interventions: Drug: PRO 140;   Drug: Placebo
16 Recruiting Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs. Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation
Condition: GVHD
Intervention: Drug: Telmisartan
17 Recruiting Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD
Condition: Graft vs Host Disease
Intervention: Drug: Pregnyl®
18 Not yet recruiting Safety Study of Preimplantation Factor (PIF-1) to Treat Acute Steroid-Resistant Graft-Versus-Host Disease (GVHD)
Condition: Graft Vs Host Disease
Intervention: Drug: Preimplantation factor (PIF-1)
19 Recruiting BMT Auto MSCs GvHD Ph 1
Conditions: Graft Versus Host Disease;   Acute Graft Versus Host Disease;   Chronic Graft Versus Host Disease
Intervention: Biological: Autologous mesenchymal stromal cells (MSCs)
20 Recruiting A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Condition: Graft-versus-host Disease
Interventions: Drug: Ruxolitinib;   Drug: Prednisone or methylprednisolone

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.